The DNA methyltransferase 1 (DNMT1)/miR-34a axis promoted carcinogenesis of various types of cancers. However, no literature reported its contribution to the stemness of osteosarcoma cancer stem-like cells (OSLCs). We sought to determine whether the DNMT1/miR-34a axis facilitates the stemness of OSLCs. We here revealed the higher DNMT1 activity and expression, lower miR-34a expression with high methylation of its promoter, and stronger stemness of OSLCs, as manifested by elevated sphere and colony formation capacities; CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 protein amounts in vitro; and carcinogenicity in a nude mouse xenograft model, when compared to the parental U2OS cells. 5-Azacytidine (Aza-dC) repressed DNMT1 activation and upregulated miR-34a expression by promoter demethylation and suppressed the stemness of OSLCs in a dose-dependent manner. DNMT1 knockdown increased miR-34a and reduced the stemness of OSLCs. Transfection with a miR-34a mimic repressed the stemness of OSLCs but did not alter DNMT1 activity and expression. Conversely, DNMT1 overexpression declined miR-34a levels, promoting the stemness of U2OS cells. Transfection with a miR-34a inhibitor enhanced the stemness of U2OS cells, without affecting the DNMT1 activity and expression. Importantly, reexpression of miR-34a could rescue the effects of DNMT1 overexpression on miR-34a inhibition as well as the stemness promotion without affecting the activity and expression of DNMT1. Our results revealed that aberrant activation of DNMT1 caused promoter methylation of miR-34a, leading to miR-34a underexpression, and the role of the DNMT1/miR-34a axis in promoting and sustaining the stemness of OSLCs.
Introduction
Osteosarcoma (OS) is the most common bone-derived solid cancer in children and adolescents and originates from mesenchymal cells of osteoblast origin [1, 2] . The long-term survival of OS patients remains to have no significant improvements due to metastases and chemoresistance [3] . Accumulating evidence supported the notion that a small subpopulation of cells with stem-like characteristics called cancer stem-like cells (CSLCs) are the most cause for cancer metastasis and chemoresistance owing to their stronger stemness [4] . Therefore, it is necessary to urgently clarify the underlying cellular and molecular mechanisms to facilitate and sustain the stemness of OS cells.
MicroRNAs (miRNAs) regulate the function and property of CSLCs, and dysregulation was involved in the stemness of prostate cancer and Ewing's sarcoma [5, 6] . For instance, downregulated miR-200b, miR-200c, and miR-145 act as tumor suppressors in the upregulation of pluripotency in maintaining factors, such as Bmi1, Oct4, c-Myc, and Sox2, thereby conferring the capacities of self-renewability and colony formation in CSLCs [7] . Recent studies have reported that miR-34a is underexpressed in various cancers such as Ewing's sarcoma [8] , colorectal cancer [9] , and OS [10, 11] . miR-34a also regulated colon CSLCs [12] and inhibited breast cancer stemness [13] . Liu et al. demonstrated that miR-34a inhibits prostate CSLCs by directly repressing CD44 [14] . The study by Zhang et al. [15] revealed that human urothelial bladder cancer stemness was reduced by miR-34a. According to a recent study by Zou et al., the elevated self-renewal ability of human OS stem-like cells (OSLCs) was involved in miR-34a underexpression of these cells [11] . Despite the above studies on miR-34a, the upstream event and regulation of miR-34a in OSLCs are still unclear.
Most recent studies showed that epigenetic modifications are responsible for cancer initiation and progression by regulating the stemness of CSLCs [16] [17] [18] . Aberrant DNA methylation promotes the self-renewable capacity of ovarian CSLCs [16, 19] . DNA methyltransferase 1 (DNMT1) contributed to the maintenance of stemness of various CSLCs [20] [21] [22] [23] [24] [25] , including OSLCs [10, 11] . According to a study using mammary gland-specific DNMT1-knockout mice, DNMT1 deletion limited the CSLC population and reduced mammary tumorigenesis [20] . Notably, tumor-suppressive miRNAs could be silenced by DNA hypermethylation in the promoter regions [26] [27] [28] [29] . Recent studies showed that miR-34a promoter hypermethylation led to epigenetic inactivation [30] [31] [32] [33] . Considering the regulation of stemness of OSLCs by miR-34a [10, 11] , we hypothesized that it may be possible to repress the stemness by upregulating miR-34a through inactivating DNMT1 in human OS cells and their derived OSLCs. We here sought to determine whether the DNMT1/miR-34a axis promotes the stemness of OSLCs.
Materials and Methods

Cell and Sphere
Culture. Human osteosarcoma U2OS cells (Cell Bank of Chinese Academy of Sciences, Shanghai, China) were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS, Gibco) and penicillin (100 IU/ml)/streptomycin (100 μg/ml) at 37°C in 5% CO 2 .
For sphere culture, U2OS cells (1 × 10 3 ) were suspended in the cancer stem cell-conditioned medium (CSC-CM) composed of serum-free DMEM/F12 (Invitrogen, Carlsbad, CA, USA) with 100 IU/ml penicillin, 100 μg/ml streptomycin, 20 ng/ml hrEGF (Invitrogen), 20 ng/ml hbFGF (Invitrogen), 2% B27 (Invitrogen), 0.4% BSA (Invitrogen), and 4 μg/ml insulin (Sigma-Aldrich) to form spheres. The sphere-forming U2OS cells obtained from the sphere formation culture were called OSLCs as described by Zou et al. [11] .
2.2. DNMT1 Activity Detection. Nuclear extracts from OSLCs (1 × 10 6 ) or U2OS cells (1 × 10 6 ) were obtained by the EpiQuik™ Nuclear Extraction Kit (cat. OP-0002-1; EpiGentek Group Inc., Farmingdale, NY, USA). DNMT1 activity is nonradioactively measured by using a DNA Methyltransferase Activity/Inhibition Assay Kit (cat. P-3001; EpiGentek Group Inc., Farmingdale, NY, USA) according to the protocol. DNMT activity was calculated by using the formula, which was as follows: DNMT activity ðOD/h/mgÞ = ðno inhibitor OD − blank ODÞ 1000/protein amount ðμgÞ × hour. Relative activity of DNMT1 was normalized by the activity of U2OS cells or untreated OSLCs. ). The protein concentrations were determined by the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Electrophoresis with sodium dodecyl sulfatepolyacrylamide gel (10%, SDS-PAGE) was used to separate the lysate (40 μg protein), which was then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore). The membranes were then blocked with TBST containing 5% BSA for 2 h at room temperature and then incubated with primary antibodies anti-β-actin (1 : 5000; catalog no. A5441; Sigma-Aldrich), anti-CD133, anti-CD44, anti-ABCG2, anti-DNMT1, anti-Bmi1, anti-Sox2, and anti-OCT4 (1 : 2000; catalog nos. 5860S, 3570S, 4477S, 3598S, 5856, 2748, and 2840 CST) overnight at 4°C. The membranes were then incubated with appropriate HRP-conjugated secondary antibodies (Beyotime Institute) for 1 h. The protein bands were visualized using an enhanced chemiluminescence kit (Amersham Biosciences) by using an enhanced chemiluminescence detection system (Ranon GIS-2008, Tanon Science & Technology Co., Ltd., Shanghai, China).
Quantitative Real-Time PCR.
Total RNA from U2OS cells (1 × 10 6 ) or OSLCs (1 × 10 6 ) was extracted using the TRIzol universal reagent (cat. DP424, Tiangen Biotech, Beijing, China), and miRNA was obtained by a miRcute miRNA isolation kit (cat. DP501, Tiangen Biotech, Beijing, China) following the manufacturer's instructions.
For mRNA detection, total RNA (2 μg) was transcribed into cDNA using the SureScript™ first-strand cDNA synthesis kit (cat. QP057, GeneCopoeia Inc., Maryland, USA). The BlazeTaq™ One-Step SYBR Green qRT-PCR kit (cat. QP047, GeneCopoeia Inc., Maryland, USA) was employed to amplify cDNA on a CFX Connect fluorescent quantitative PCR analyzer (Bio-Rad Laboratories). The primers used are listed in Supplementary Table S1 . The cycling variables were set as follows: 95°C for 10 min, followed by 35 cycles of 95°C (30 sec), 55°C (30 sec), and 70°C (30 sec). Human β-actin RNA was used as an internal control for RNA normalization.
For determination of microRNA, miRNA (2 μg) was transcribed into cDNA using the All-in-One™ miRNA qRT-PCR detection kit (cat. QP016, GeneCopoeia Inc., Maryland, USA) including the All-in-One miRNA qRT-PCR detection kits and the All-in-One miRNA first-strand cDNA synthesis kits. U6 RNA was used as an internal control. Primers used are depicted in Supplementary Table S2 . The results were analyzed by the method of 2 -ΔΔCt .
Methylation-Specific PCR (MSP)
. Cellular DNA of U2OS cells (1 × 10 6 ) or OSLCs (1 × 10 6 ) was isolated using DNA-EZ reagents V All-DNA-Out (Sangon Biotech, Shanghai, China). Genomic DNA was treated with the Methylamp One-Step DNA Modification Kit (EpiGentek, NY, USA) following the manufacturer's instructions. HotStarTaq Polymerase (Qiagen, Germany) was used to amplify PCR, and Sangon Biotech Co., Ltd. (Shanghai, China) designed and provided the methylated and unmethylated PCR primers to determine the methylation of the miR-34a promoter. The sequences of PCR primers specific for methylated and unmethylated alleles of miR-34a are shown in Supplementary  Table S3 . The products of MSP were visualized by 2.0% agarose gel electrophoresis (0.5 μg/ml ethidium bromide). UV gel electrophoresis and an image analysis system (Tanon 1600 full-automatic digital gel image analysis system) were used for image analysis. micrON™ miR-34a mimic/micrOFF™ miR-34a inhibitors were obtained from RiboBio (Guangzhou, China) and were transfected into OSLCs or U2OS cells with the ibo-FECT™ CP reagent (RiboBio Co., Ltd., Guangzhou, China) at a final concentration of 50/100 nM following the manufacturer's instructions. The transfection protocol for miR34a mimic NC/miR-34a inhibitor NC that served as a negative control was the same as that for miR-34a-5p mimic/inhibitors. 3 ) into the right flank, respectively. After 2 months, the mice were euthanized and xenografts were collected. The xenografts were weighed after extraction, and the largest diameters exceeded 1.5 cm of OSLC xenografts.
To estimate the effect of DNMT1 inhibition on the tumor growth derived from OSLCs in vivo, the mice were subcutaneously injected with 100 μl phosphate buffer (PBS) containing OSLCs stably expressing DNMT1 shRNA or red fluorescein protein (1 × 10 5 cells). Each group was composed of 3 mice with 6 sites (n = 6).
To examine the effect of miR-34a on tumor growth of OSLCs in vivo, the mice were subcutaneously injected with 100 μl PBS containing OSLCs stably expressing red fluorescein protein (1 × 10 5 cells). When the xenograft size exceeded 200 mm 3 , the mice were weekly intratumorally injected with 1 nmol (in 50 μl PBS) per site of micrON™ agomir-34a (RiboBio Co., Ltd., Guangzhou, China) in a total of 3 times as the experiment group and micrON™ agomir-NC as the control group constituting 3 mice at 6 sites (n = 6) in each group. We monitored the tumor size using the IVIS Lumina III in vivo imaging system (PerkinElmer Inc., NY, USA), and then, it was photographed. The shooting mode was kept as fluorescence mode, with a peak wavelength of excitation of 587 nm and with a peak wavelength of emission of 610 nm, and the exposure time was 0.1 s. The fluorescence intensity was recorded and analyzed by living images by in vivo imaging software (PerkinElmer Inc., NY, USA). The xenografts were extracted, weighed, and frozen or fixed for further analysis. mean ± standard deviation (SD). Comparisons with the control groups were performed using two-tailed Student's t-test. All the pairwise comparisons between the groups were analyzed by Tukey's post hoc test using one-way analysis of variance (abbreviated as one-way ANOVA). Significance was determined as p < 0:05.
Results
DNMT1 Activation and miR-34a Underexpression Are
Associated with a Cancer Stem-like Cell (CSLC) Feature in the U2OS Cell Line. DNMT1 plays an essential role in CSLC feature maintenance and frequently decreased miR-34a expression in CSLCs [10] [11] [12] [13] [14] [15] [22] [23] [24] [25] . So, we initially compared the DNMT activation as well as miR-34a expression and promoter methylation between OSLCs (the sphere-forming U2OS cells) and U2OS cells (the monolayer U2OS cells). Among the DNMTs (DNMT1, DNMT3a, and DNMT3b), the activities of DNMT1 were markedly elevated by up to 23-fold in OSLCs when compared to U2OS cells (Figure 1(a) ). Stronger DNMT1 activation was also shown in OSLCs than in U2OS cells (Figures 1(b) and 1(c) ). In contrast, decreased expression and increased promoter methylation of miR-34a were observed in OSLCs relative to U2OS cells (Figures 1(d) and 1(e) ). Altogether, these findings suggested that OSLCs exhibited an increased DNMT1 activity and decreased miR-34a expression relative to U2OS cells. To estimate whether the OSLCs possess strong stemness, we next compared the capabilities of sphere formation and clonogenicity and expression levels of CSLC-related markers (CD133, CD44, and ABCG2) and pluripotent maintaining factors (Bmi1, Sox2, and Oct4) between OSLCs and U2OS cells. Enhanced capacities of sphere formation and clonogenicity (Figures 1(f) and 1(g) ) and upregulated expressions of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 (Figures 1(h) and 1(i) ) were observed in OSLCs when compared to U2OS cells. More importantly, the carcinogenicity in vivo was significantly heightened in OSLCs relative to U2OS cells (Figures 2(a)-2(d) ). However, H&E staining revealed that the histological features of xenograft tumors induced by OSLCs were similar to those induced by the U2OS cells (Figure 2(e) ). Collectively, these results indicated that the sphere-forming U2OS cells could enrich CSLCs and are used as OSLCs in further experiments.
DNMT Activation in the Acquisition and Maintenance of Stemness in OSLCs.
To evaluate the effects of DNMT1 activation on miR-34a expression, miR-34a levels in OSLCs treated with or without the DNMT1 inhibitor 5-Aza-2′-deoxycytidine (Aza-dC) were evaluated. The reduced activity (Figure 3(a) ) and expression of DNMT1 (Figures 3(b) and 3(c)) were consistent with the elevated miR-34a levels ( Figure 3(d) ) and reduced its promoter methylation (Figure 3(e) ) in Aza-dC-treated OSLCs. Altogether, these data suggested that DNMT1 repression could increase miR34a expression possibly by reducing its promoter methylation level in OSLCs.
To examine whether DNMT1 activation was required for the acquisition of a CSLC feature, we next examined the inhibition of DNMT1 activity by Aza-dC on the capacities of sphere formation and clonogenicity and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 in OSLCs. The results showed that Aza-dC declined the capacities of sphere formation and clonogenicity (Figures 3(f) and 3(g) ) and the amounts of CD133, CD44, and ABCG2 (Figure 3(h) ) as well as Bmi1, Sox2, and Oct4 (Figure 3(i) ) of OSLCs, in a dose-dependent manner. Collectively, these results revealed that DNMT1 inhibition by Aza-dC effectively diminished the stemness of OSLCs.
To further determine the effects of DNMT1 activation on miR-34a expression, we generated OSLCs with shDNMT1 or shNC to examine DNMT1 and miR-34a expressions. Both mRNA and protein levels of DNMT1 in OSLCs expressing DNMT1 shRNA showed significant reduction (Figures 4(a) and 4(b)) and were consistent with the increased expression of miR-34a (Figure 4(c) ) relative to NC shRNA or untreated control OSLCs. Altogether, our data showed that DNMT1 knockdown by transducing DNMT1 shRNA could upregulate miR-34a expression in OSLCs.
To further validate the effects of DNMT1 activation on the stemness, we assessed the knockdown of DNMT1 by expressing DNMT1 shRNA on the capacities of sphere formation and clonogenicity and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4. The capacities of sphere formation and clonogenicity (Figures 4(d) and 4(e) ) and the amounts of CD133, CD44, and ABCG2 (Figure 4(f) ) as well as Bmi1, Sox2, and Oct4 (Figure 4 (g)) were declined in OSLCs expressing DNMT1 shRNA relative to NC shRNA or untreated control OSLCs. More importantly, the in vivo carcinogenicity was significantly inhibited by DNMT1 knockdown in the nude mouse model of OSLCs (Figure 4(h) ). Collectively, these results revealed that knockdown of DNMT1 by expressing DNMT1 shRNA effectively diminished the stemness of OSLCs.
To further confirm the influence of DNMT1 activation on miR-34a expression, U2OS cells with ectopic expression of DNMT1 were generated to compare the expressions of DNMT1 and miR-34a relative to vector control or untreated 
miR-34a Underexpression May Mediate the Promotion of
Stemness Induced by DNMT1 Activation in OSLCs. To examine whether alteration of miR-34a expression affects DNMT1 activity and expression, OSLCs were transfected with a miR34a mimic (miR-34a) or miR-34a mimic negative control (miR-NC). The results showed that miR-34a (Figure 6(a) ) was upregulated, whereas the activity (Figure 6(b) ) and expressions of DNMT1 (Figures 6(c) and 6(d) ) showed no significant alterations in OSLCs transfected with miR-34a when compared to miR-NC or untreated control OSLCs. Altogether, our results indicated that miR-34a showed no effect on the DNMT1 activation of in OSLCs.
To assess the influences of miR-34a on the acquisition of stemness, we next examined whether miR-34a ectopic expression reduces the capacities of sphere formation and clonogenicity and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4. The results revealed a decrease in the capacities of sphere formation and clonogenicity (Figures 6(e) and 6(f) ) and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 (Figures 6(g) and 6 (h)) in OSLCs transfected with miR-34a relative to miR-NC or untreated control. More importantly, the carcinogenicity in vivo was significantly inhibited in the OSLC nude mouse model by intratumoral injection with agomir-34a ( Figure 6(i) ). Collectively, these results indicated that stemness of OSLCs can be inhibited by miR-34a.
To further determine the influence of miR-34a on DNMT1 activation, U2OS cells were transfected with a miR-34a inhibitor (anti-34a) or miR-34a inhibitor negative control (Anti-NC). The results showed that miR-34a (Figure 7(a) ) was significantly downregulated, whereas the activity (Figure 7(b) ) and expressions of DNMT1 (Figures 7(c) and 7(d) ) showed no differences in U2OS cells transfected with anti-34a relative to anti-NC or untreated U2OS cells. Altogether, our results indicated that miR-34a knockdown did not affect DNMT1 activation in U2OS cells.
To further evaluate the role of miR-34a in the acquisition of stemness, we examined whether anti-34a enhances the capacities of sphere formation and clonogenicity and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 in U2OS cells. The results showed an increase in the capacities of sphere formation and clonogenicity (Figures 7(e) and 7(f)) and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 (Figures 7(g) and 7 (h)) in U2OS cells transfected with anti-34a relative to anti-NC or untreated cells. Collectively, our data indicated that the stemness of U2OS cells might depend on the miR-34a state in U2OS cells.
In order to provide convincing evidence that the inhibition of miR-34a by overexpressing DNMT1 promotes stemness, U2OS cells overexpressing DNMT1 were transfected with miR-34a followed by examining miR-34a and DNMT expression. Transfection of U2OS cells with miR-34a abrogated the overexpressing DNMT1-associated repression on miR-34a expression (Figure 8(a) ), whereas elevated DNMT1 expression levels (Figures 8(b) and 8(c) ) by DNMT1overex-pression showed no changes. These results demonstrated that alterations of miR-34a expression were considered a downstream event of DNMT1 in U2OS cells.
To clearly prove that inhibition of miR34a by overexpressing DNMT1 promotes the stemness, U2OS cells overexpressing DNMT1 were transfected with miR-34a and the capacities of sphere formation and clonogenicity and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 were examined. The results demonstrated that transfection of U2OS cells with miR-34a reversed the overexpressing DNMT1-associated promotion on the stemness, such as enhancing the capacities of sphere formation and clonogenicity (Figures 8(d) and 8(e) ) and the amounts of CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 (Figures 8(f) and  8(g) ). Collectively, our data confirmed that miR-34a was one of the downstream effectors of DNMT1 for the acquisition and maintenance of stemness of U2OS cells.
Discussion
In the present study, the hypermethylation of the miR-34a promoter by abnormal activation of DNMT1 led to miR34a underexpression in OSLCs compared to the corresponding OS cells, and miR-34a reexpression suppressed the stemness of OSLCs both in vitro and in vivo. Our results suggested that the DNMT1/miR-34a signaling axis exerts a crucial role in OS carcinogenesis, especially in the process of promoting and sustaining the stemness of OSLCs. Aberrant expressions of miRNAs are involved in the regulation of stemness in various cancers by controlling stemness-related gene expressions [10, 11, 14, [34] [35] [36] [37] [38] [39] [40] . miR34a has been recognized as a tumor-suppressive miRNA and reduced carcinogenesis in a variety of cancers, including OS [30] [31] [32] [33] . Underexpression of miR-34a has been implicated in maintaining the stemness of CSLCs [14, 15] , especially in OS cells [10, 11] . In the current study, we demonstrated that miR-34a was underexpressed in OSLCs compared with corresponding U2OS cells, and miR-34a reexpression could repress the capacities of sphere and clonogenic formation as well as downregulated stemnessrelated genes including CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4. These results underlined that miR-34a mimics or modulator upregulated miR-34a, which might be a promising agent against human OS that targets OSLCs.
The pivotal role of DNMT1 in the regulation and stemness of CSLCs has been well documented in various tumors, including leukemia [41] , breast cancer [42] , hepatocelluar cancer [43] , non-small-cell lung cancer [44] , and pancreatic adenocarcinoma [45] and OS [46] . Interestingly, the study by Peng et al. [33] showed that DNMT1 overexpression resulted in dramatic downregulation by hypermethylation of the miR-34a promoter, which promoted the stemness in breast cancer. According to a study, miR-148a inhibited the differentiation and proliferation of CSLCs derived from primary OS cells by directly targeting DNMT1 [29] . However, few other studies have examined the promotion of stemness by downregulated miR-34a through aberrant expression of DNMT1 in OSLCs and OS cells. The present study provided evidence that DNMT1 was significantly activated, leading to the underexpression of miR-34a through hypermethylation of its promoter in OSLCs when compared with corresponding OS cells. Meanwhile, a higher carcinogenicity was observed as indicated by stronger capacities of sphere and clonogenic formation, and stronger stemness was also displayed as demonstrated by highly expressed stemnessrelated genes such as CD133, CD44, ABCG2, Bmi1, Sox2, and Oct4 in vitro in OSLCs than in the corresponding OS cells. Our results suggested for the first time that the DNMT1/miR-34a axis substantially promoted the stemness in OSLCs and highlighted the role of the DNMT1/miR-34a axis in the treatment for OS targeting OSLCs.
In OS cells, many studies showed that miR-34a targeted a variety of oncogenes including certain stemness-related genes such as CD44 [14] and Sox2 [10] . Zhao et al. [47] utilized genetically engineered pre-miRNA-34a prodrug to demonstrate repression of miR-34a on tumor growth of an orthotopic OS xenograft nude model in vivo. Although that the targets of miR-34a repressed the stemness of OSLCs requires further exploration, we here demonstrated that the tumor growth in subcutaneous nude mouse xenograft models of OSLCs was suppressed by treatment with either the DNMT1 inhibitor Aza-dC or agomir-34a. Our results suggested that phenocopied miR-34a or inactivated DNMT1 or both may be a promising potential approach targeting OSLCs for human OS treatment.
In summary, our study has gained insights into DNMT1 overexpression that led to miR-34a methylation silence, promoting the stemness of OS cells and their derived OSLCs. It is appealing to consider that the epigenetic-based reprogramming applications in the treatment of solid tumors can promote the development of alternative therapies targeting OSLCs for inoperable or drug-resistant OS.
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